Vaccine Research Study
Researchers at the NYU Langone Health are conducting a study to test a new vaccine designed to protect women and their newborns from serious infections caused by Group B streptococcus (GBS).
Fast Facts
Not currently pregnant, breastfeeding or planning to become pregnant in the next 6 months
18-49 Years Old
Compensation Provided
Conducted in New York, NY
Study Background
Researchers at the NYU Langone Health are conducting a study to test a new vaccine designed to protect women and their newborns from serious infections caused by Group B streptococcus (GBS).
This study is focused on testing a new vaccine, IVT GBS-06, which is designed to protect women of childbearing age from a common bacterium called Group B streptococcus (GBS). GBS can cause serious infections, especially in newborns, since about 1 in 5 women carry this bacterium without knowing it. During childbirth, it can be passed to the baby, leading to dangerous illnesses like sepsis, pneumonia, or meningitis. This study aims to find a safe and effective way to help prevent these infections.
The goal is to learn how well the vaccine works, how the body responds to it, and whether it’s safe for women to use. By understanding this, we hope to offer better protection for both mothers and their babies, helping to prevent life-threatening infections in the future.
ID: NCT06611371
Study Background
Researchers at the NYU Langone Health are conducting a study to test a new vaccine designed to protect women and their newborns from serious infections caused by Group B streptococcus (GBS).
This study is focused on testing a new vaccine, IVT GBS-06, which is designed to protect women of childbearing age from a common bacterium called Group B streptococcus (GBS). GBS can cause serious infections, especially in newborns, since about 1 in 5 women carry this bacterium without knowing it. During childbirth, it can be passed to the baby, leading to dangerous illnesses like sepsis, pneumonia, or meningitis. This study aims to find a safe and effective way to help prevent these infections.
The goal is to learn how well the vaccine works, how the body responds to it, and whether it’s safe for women to use. By understanding this, we hope to offer better protection for both mothers and their babies, helping to prevent life-threatening infections in the future.
ID: NCT06611371
Additional Information
This study is being done to develop a vaccine that can safely and effectively protect women of childbearing age and their future newborns from serious infections caused by Group B streptococcus (GBS), a bacterium that can lead to life-threatening illnesses in infants, such as sepsis, pneumonia, and meningitis. By understanding the vaccine’s effectiveness and safety, researchers aim to reduce the risk of GBS-related infections and improve health outcomes for mothers and babies.
You may qualify for a study if you meet the following criteria.
Inclusion Criteria:
- Women ages 18-49
- Not currently pregnant, breastfeeding or planning to become pregnant in the next 6 months
- Generally healthy
- No history of severe reaction associated with a vaccine
- Not immunocompromised with known or suspected immunodeficiency
- No history of coagulation or blood disorder that could cause anemia or excessive bleeding
If you decide to participate in this study, you will be asked to complete a minimum of 7 in-person study visits over a period of approximately 7 months.
As a participant, you can receive up to $770:
- You will be reimbursed $110 per each in-person study visit completed
There is no cost for you to participate in our research study.